Skip Navigation



Annals of Oncology Advance Access published online on September 15, 2006
Annals of Oncology, doi:10.1093/annonc/mdl297
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/11/1705    most recent
mdl297v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mustacchi, G.
Right arrow Articles by Sisto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mustacchi, G.
Right arrow Articles by Sisto, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received May 23, 2006
Revised July 6, 2006
Accepted July 7, 2006

original article

An induction dose of epoetin {alpha} of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy

G. Mustacchi 1 *, R. Ceccherini 1, C. Dellach 1, S. Foladore 1, S. Milani 1, M. Leita 1, and M. Sisto 1

1 Universita' di Trieste, Centro Oncologico ASS1 triestina, Italy

* To whom correspondence should be addressed.
G. Mustacchi, E-mail: g.mustacchi{at}fmc.units.it


  Abstract

Background: This pilot study was conducted to evaluate the feasibility, activity, and safety of an induction dose of epoetin {alpha} in cancer patients with moderate or severe anemia who were receiving chemotherapy.

Patients and methods: Thirty patients with solid tumors and hemoglobin (Hb) levels <11.0 g/dl were enrolled. Patients received single s.c. injections of epoetin {alpha}, 40 000 IU for three consecutive days, and were then observed for the following 30 days. The primary efficacy variable was the response rate (Hb increase ≥1 g/dl) at day 15. Secondary efficacy variables included the proportion of patients given blood transfusions between baseline and the end of study, the duration of response (Hb level ≥1 g/dl), and ability to maintain the planned chemotherapy dose (dose intensity).

Results: At day 15, 23 of 30 (77%) patients had achieved increases in Hb levels of at least 1 g/dl. The mean Hb increase in responders was 2.0 g/dl [95% confidence interval (CI) = 1.7-2.3 g/dl]. The Hb increase was 2.3 ± 0.7 g/dl in responders with baseline Hb levels <9.5 g/dl (median Hb value), and 1.7 ± 0.6 g/dl in those with higher Hb levels (P = 0.012). The median duration of response was 6.1 weeks (95% CI = 1.6-10.6 weeks). Hematologic parameters were not significantly changed in nonresponders. Multivariate analysis detected no significant differences in Hb increase at day 15 on the basis of age, sex, weight, baseline Hb levels, type or stage of tumor, or treatment with platinum-based chemotherapy. No serious adverse event related to epoetin {alpha} treatment was observed.

Conclusions: We conclude that a higher initial dosing of epoetin {alpha} appears to be an efficient schedule for treating anemia in cancer patients undergoing chemotherapy, conferring higher response rates than those seen with standard doses. Further evaluation of these and other epoetin {alpha} dosage regimens is warranted.

Keywords: anemia; chemotherapy; epoietin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.